This was announced by the Mainz-based German company Biontech and its US partner Pfizer (New York) on Friday. The vaccine combines an mRNA-based influenza vaccine with a corona vaccine adapted to both the currently predominant omicron sublines BA.4/BA.5 and to the wild type.
At the beginning of November, the two companies announced the start of a phase 1 study of the vaccine. Around 180 people between the ages of 18 and 64 should take part in the USA.
more from health
Flu wave in Austria continued to pick up speed
Doctor, does the solar plexus really exist?
Mononucleosis: Chronic fatigue as a result?
Corona: “A completely different disease than a year ago”
My themes
For your saved topics
found new items.
info By clicking on the icon you add the keyword to your topics.
info
Click on the icon to open your “My Topics” page. They have of 15 tags saved and would have to remove tags.
info By clicking on the icon you remove the keyword from your topics.
Add the theme to your themes.
Source: Nachrichten
